Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

ratiopharm gmbh - levocetirizina - levocetirizina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

cipla europe nv - levocetirizina - levocetirizina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - levocetirizina - levocetirizina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aurobindo pharma (italia) s.r.l. - levocetirizina - levocetirizina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - levocetirizina - levocetirizina

Unione Europea - italiano - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenti antineoplastici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Unione Europea - italiano - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedema, ereditario - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, polmone non a piccole cellule - agenti antineoplastici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Unione Europea - italiano - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemia, mieloide - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Unione Europea - italiano - EMA (European Medicines Agency)

laboratoires delbert - istamina dicloridrato - leucemia, mieloide, acuta - immunostimolanti, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). l'efficacia di ceplene non è stata pienamente dimostrata in pazienti di età superiore ai 60 anni.